On the public citation graph

Repurposing existing therapeutics, its importance in oncology drug development: Kinases as a potential target

0 signed · 124 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1001/jamanetworkopen.2018.6875openalex-snapshot
Comparison of Sales Income and Research and Development Costs for FDA-Approved Cancer Drugs Sold by Originator Drug Companies
inferredcites →https://doi.org/10.1002/9781118274408openalex-snapshot
Drug Repositioning
inferredcites →https://doi.org/10.1002/hep.29496openalex-snapshot
Recent developments of c‐Met as a therapeutic target in hepatocellular carcinoma
inferredcites →https://doi.org/10.1002/prp2.620openalex-snapshot
Buying time: Drug repurposing to treat the host in COVID‐19H
inferredcites →https://doi.org/10.1007/s00277-015-2412-1openalex-snapshot
Repurposing medicinal compounds for blood cancer treatment
inferredcites →https://doi.org/10.1007/s11095-008-9661-9openalex-snapshot
Cancer is a Preventable Disease that Requires Major Lifestyle Changes
inferredcites →https://doi.org/10.1016/j.celrep.2015.12.080openalex-snapshot
Kinase Inhibitor Profiling Reveals Unexpected Opportunities to Inhibit Disease-Associated Mutant Kinases
inferredcites →https://doi.org/10.1016/j.chembiol.2012.12.006openalex-snapshot
Developing Irreversible Inhibitors of the Protein Kinase Cysteinome
inferredcites →https://doi.org/10.1016/j.ddstr.2011.10.002openalex-snapshot
Drug repurposing from an academic perspective
inferredcites →https://doi.org/10.1016/j.drudis.2015.07.008openalex-snapshot
Small-molecule kinase inhibitors: an analysis of FDA-approved drugs
inferredcites →https://doi.org/10.1016/j.drudis.2015.09.017openalex-snapshot
Drug-repositioning opportunities for cancer therapy: novel molecular targets for known compounds
inferredcites →https://doi.org/10.1016/j.drudis.2018.11.022openalex-snapshot
The drug repurposing landscape from 2012 to 2017: evolution, challenges, and possible solutions
inferredcites →https://doi.org/10.1016/j.semcancer.2020.04.006openalex-snapshot
Repurposing of drugs: An attractive pharmacological strategy for cancer therapeutics
inferredcites →https://doi.org/10.1016/j.soncn.2017.02.002openalex-snapshot
Cancer Screening and Early Detection in the 21st Century
inferredcites →https://doi.org/10.1016/j.tips.2013.06.005openalex-snapshot
Cancer drug discovery by repurposing: teaching new tricks to old dogs
inferredcites →https://doi.org/10.1016/j.tips.2014.09.007openalex-snapshot
Advances in kinase targeting: current clinical use and clinical trials
inferredcites →https://doi.org/10.1016/j.tips.2015.04.005openalex-snapshot
FDA-approved small-molecule kinase inhibitors
inferredcites →https://doi.org/10.1016/j.trecan.2017.06.007openalex-snapshot
Repurposing Drugs in Oncology: Next Steps
inferredcites →https://doi.org/10.1016/s1359-6446(04)03307-0openalex-snapshot
Thalidomide as a novel therapeutic agent: new uses for an old product
inferredcites →https://doi.org/10.1038/534314aopenalex-snapshot
Can you teach old drugs new tricks?
inferredcites →https://doi.org/10.1038/bjc.2012.581openalex-snapshot
Cancer heterogeneity: implications for targeted therapeutics
inferredcites →https://doi.org/10.1038/nbt.1990openalex-snapshot
Comprehensive analysis of kinase inhibitor selectivity
inferredcites →https://doi.org/10.1038/nbt.2017openalex-snapshot
Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity
inferredcites →https://doi.org/10.1038/nbt.3374openalex-snapshot
Comprehensive characterization of the Published Kinase Inhibitor Set
inferredcites →https://doi.org/10.1038/nbt1068openalex-snapshot
A small molecule–kinase interaction map for clinical kinase inhibitors
inferredcites →https://doi.org/10.1038/nbt1358openalex-snapshot
A quantitative analysis of kinase inhibitor selectivity
inferredcites →https://doi.org/10.1038/nrc2559openalex-snapshot
Targeting cancer with small molecule kinase inhibitors
inferredcites →https://doi.org/10.1038/nrc2787openalex-snapshot
Targeting the cancer kinome through polypharmacology
inferredcites →https://doi.org/10.1038/nrclinonc.2015.169openalex-snapshot
Drug repurposing in oncology—patient and health systems opportunities
inferredcites →https://doi.org/10.1038/nrd.2018.168openalex-snapshot
Drug repurposing: progress, challenges and recommendations
inferredcites →https://doi.org/10.1038/nrd.2018.21openalex-snapshot
Kinase inhibitors: the road ahead
inferredcites →https://doi.org/10.1038/nrd1468openalex-snapshot
Drug repositioning: identifying and developing new uses for existing drugs
inferredcites →https://doi.org/10.1038/nrd1470openalex-snapshot
Can the pharmaceutical industry reduce attrition rates?
inferredcites →https://doi.org/10.1038/nrd2030openalex-snapshot
Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond
inferredcites →https://doi.org/10.1038/nrd2758openalex-snapshot
Do molecularly targeted agents in oncology have reduced attrition rates?
inferredcites →https://doi.org/10.1038/nrd3744openalex-snapshot
Outlook for the next 5 years in drug innovation
inferredcites →https://doi.org/10.1038/nrd4707openalex-snapshot
Pioneering government-sponsored drug repositioning collaborations: progress and learning
inferredcites →https://doi.org/10.1038/nrurol.2012.185openalex-snapshot
The complexity of prostate cancer: genomic alterations and heterogeneity
inferredcites →https://doi.org/10.1038/s41392-020-00213-8openalex-snapshot
Overcoming cancer therapeutic bottleneck by drug repurposing
inferredcites →https://doi.org/10.1038/s41416-018-0045-6openalex-snapshot
New opportunities for kinase drug repurposing and target discovery
inferredcites →https://doi.org/10.1038/s41586-020-2577-1openalex-snapshot
Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing
inferredcites →https://doi.org/10.1038/s43018-019-0018-6openalex-snapshot
Discovering the anticancer potential of non-oncology drugs by systematic viability profiling
inferredcites →https://doi.org/10.1042/bj20121418openalex-snapshot
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery
inferredcites →https://doi.org/10.1056/nejm199911183412102openalex-snapshot
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
inferredcites →https://doi.org/10.1080/15384047.2017.1385680openalex-snapshot
Persistence of DNA adducts, hypermutation and acquisition of cellular resistance to alkylating agents in glioblastoma
inferredcites →https://doi.org/10.1093/jnci/djq495openalex-snapshot
Projections of the Cost of Cancer Care in the United States: 2010-2020
inferredcites →https://doi.org/10.1111/bcp.12785openalex-snapshot
Repurposing some older drugs that cross the blood–brain barrier and have potential anticancer activity to provide new treatment options for glioblastoma
inferredcites →https://doi.org/10.1111/bcp.14551openalex-snapshot
A pharmacological framework for integrating treating the host, drug repurposing and the damage response framework in COVID‐19
inferredcites →https://doi.org/10.1111/bcp.14964openalex-snapshot
Repurposing existing therapeutics, its importance in oncology drug development: Kinases as a potential target
inferredcites →https://doi.org/10.1111/bph.14751openalex-snapshot
THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Catalytic receptors
inferredcites →https://doi.org/10.1111/bph.14752openalex-snapshot
THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Enzymes
inferredcites →https://doi.org/10.1111/jcpt.12759openalex-snapshot
Repurposing old drugs in oncology: Opportunities with clinical and regulatory challenges ahead
inferredcites →https://doi.org/10.1124/mol.114.095489openalex-snapshot
25 Years of Small Molecular Weight Kinase Inhibitors: Potentials and Limitations
inferredcites →https://doi.org/10.1126/science.aan4368openalex-snapshot
The target landscape of clinical kinase drugs
inferredcites →https://doi.org/10.1126/science.aau8768openalex-snapshot
MTOR signaling orchestrates stress-induced mutagenesis, facilitating adaptive evolution in cancer
inferredcites →https://doi.org/10.1146/annurev-pharmtox-010715-103111openalex-snapshot
Toward a Better Understanding of the Complexity of Cancer Drug Resistance
inferredcites →https://doi.org/10.1159/000350110openalex-snapshot
Skepinone-L, a Novel Potent and Highly Selective Inhibitor of p38 MAP Kinase, Effectively Impairs Platelet Activation and Thrombus Formation
inferredcites →https://doi.org/10.1172/jci76094openalex-snapshot
Targeting cancer with kinase inhibitors
inferredcites →https://doi.org/10.1182/blood-2011-02-315283openalex-snapshot
New sources of drugs for hematologic malignancies
inferredcites →https://doi.org/10.1182/blood-2015-05-646240openalex-snapshot
Profiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapse
inferredcites →https://doi.org/10.1186/1479-7364-7-20openalex-snapshot
K-Map: connecting kinases with therapeutics for drug repurposing and development
inferredcites →https://doi.org/10.1186/s12943-018-0804-2openalex-snapshot
Kinase-targeted cancer therapies: progress, challenges and future directions
inferredcites →https://doi.org/10.12793/tcp.2019.27.2.59openalex-snapshot
A review of computational drug repurposing
inferredcites →https://doi.org/10.1371/journal.pone.0132072openalex-snapshot
In Silico Identification and In Vitro and In Vivo Validation of Anti-Psychotic Drug Fluspirilene as a Potential CDK2 Inhibitor and a Candidate Anti-Cancer Drug
inferredcites →https://doi.org/10.1371/journal.pone.0165737openalex-snapshot
The Human Kinome Targeted by FDA Approved Multi-Target Drugs and Combination Products: A Comparative Study from the Drug-Target Interaction Network Perspective
inferredcites →https://doi.org/10.18632/oncotarget.22904openalex-snapshot
Identification of antipsychotic drug fluspirilene as a potential anti-glioma stem cell drug
inferredcites →https://doi.org/10.18632/oncotarget.6419openalex-snapshot
Antibiotic drug tigecycline inhibits melanoma progression and metastasis in a p21CIP1/Waf1-dependent manner
inferredcites →https://doi.org/10.18632/oncotarget.6516openalex-snapshot
Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in non-small cell lung cancer cells
inferredcites →https://doi.org/10.2217/fon.14.244openalex-snapshot
Repurposing drugs in your medicine cabinet: untapped opportunities for cancer therapy?
inferredcites →https://doi.org/10.3322/caac.21492openalex-snapshot
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
inferredcites →https://doi.org/10.3332/ecancer.2014.442openalex-snapshot
ecancermedicalscience
inferredcites →https://doi.org/10.3332/ecancer.2014.485openalex-snapshot
Repurposing drugs in oncology (ReDO)—Cimetidine as an anti-cancer agent
inferredcites →https://doi.org/10.3389/fphar.2015.00205openalex-snapshot
Multi-target pharmacology: possibilities and limitations of the “skeleton key approach” from a medicinal chemist perspective
inferredcites →https://doi.org/10.3389/fphar.2019.01664openalex-snapshot
On-Label or Off-Label? Overcoming Regulatory and Financial Barriers to Bring Repurposed Medicines to Cancer Patients
inferredcites →https://doi.org/10.3892/ijo.2018.4661openalex-snapshot
From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment (Review)
inferredcites →https://doi.org/10.3892/mmr.2015.4310openalex-snapshot
Adapalene inhibits the activity of cyclin-dependent kinase 2 in colorectal carcinoma
inferredcites →https://doi.org/10.7150/ijbs.9224openalex-snapshot
Recent Advances in Drug Repositioning for the Discovery of New Anticancer Drugs

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.1002/9781394182862.ch3openalex-snapshot
Off‐target Activity and Adverse Drug Reactions
inferred← citeshttps://doi.org/10.1002/bcp.70113openalex-snapshot
Approaches to repurposing reverse transcriptase antivirals in cancer
inferred← citeshttps://doi.org/10.1002/ccs3.70042openalex-snapshot
Pan‐cancer analysis and oncogenic implications of MGAM and MGAM2 : Toward precision oncology and drug repurposing in colorectal cancer
inferred← citeshttps://doi.org/10.1002/ijc.34181openalex-snapshot
Eventual success rate and predictors of success for oncology drugs tested in phase I trials
inferred← citeshttps://doi.org/10.1002/inm3.70033openalex-snapshot
Ovarian Cancer: Epidemiology, Disease Mechanisms, New Diagnosis and Treatment Strategies, and Research Directions
inferred← citeshttps://doi.org/10.1002/prp2.70158openalex-snapshot
A Unified Explanation for Drug Repurposing and Pharmacological Pleiotropy Based on Classical and Statistical Thermodynamics
inferred← citeshttps://doi.org/10.1007/978-981-19-5399-6_8openalex-snapshot
Drug Repurposing in Cancer
inferred← citeshttps://doi.org/10.1007/s11033-025-10716-8openalex-snapshot
Vitamin D3 augments cytotoxic effect of Itraconazole on chronic myelogenous leukemia cell line: a synergic effect on AMPK/AKT signaling pathway
inferred← citeshttps://doi.org/10.1007/s11427-024-2809-yopenalex-snapshot
Multi-omic-based classification for identifying optimal neoadjuvant treatment strategies for high-risk early-stage breast cancer
inferred← citeshttps://doi.org/10.1007/s11626-024-00983-3openalex-snapshot
Pharmacoproteogenomic approach identifies on-target kinase inhibitors for cancer drug repositioning
inferred← citeshttps://doi.org/10.1007/s12247-025-10119-zopenalex-snapshot
Repurposing Sulfonamide-Based Antidiabetic Agents Against Polycystic Ovary Syndrome: A Molecular Docking and Dynamics Simulation Approach
inferred← citeshttps://doi.org/10.1007/s40747-025-02020-6openalex-snapshot
A multimodal DTA prediction method based on triple-view contrastive learning
inferred← citeshttps://doi.org/10.1007/s44337-024-00012-yopenalex-snapshot
Drug repurposing: a retrospective revolution in breast cancer medicine
inferred← citeshttps://doi.org/10.1016/b978-0-443-33343-9.00009-0openalex-snapshot
Nanotechnology for combating chemoresistance in ovarian cancer
inferred← citeshttps://doi.org/10.1016/j.bbcan.2022.188786openalex-snapshot
AXL kinase inhibitors- A prospective model for medicinal chemistry strategies in anticancer drug discovery
inferred← citeshttps://doi.org/10.1016/j.bioorg.2026.110262openalex-snapshot
Integrative drug repositioning identifies FDA-approved inhibitors of HSP90AA1 with therapeutic potential in colorectal cancer
inferred← citeshttps://doi.org/10.1016/j.gene.2022.147106openalex-snapshot
Potential target identification for osteosarcoma treatment: Gene expression re-analysis and drug repurposing
inferred← citeshttps://doi.org/10.1016/j.jddst.2023.104767openalex-snapshot
Poly vinyl pyrrolidone (PVP) based inhaled delivery carriers for olaparib for non-small cell lung cancer (NSCLC) treatment
inferred← citeshttps://doi.org/10.1038/s41467-023-36462-8openalex-snapshot
Integrative proteomic characterization of adenocarcinoma of esophagogastric junction
inferred← citeshttps://doi.org/10.1039/d5pm00158gopenalex-snapshot
Incorporating AI, in silico , and CRISPR technologies to uncover the potential of repurposed drugs in cancer therapy
inferred← citeshttps://doi.org/10.1073/pnas.2402741121openalex-snapshot
Proteomic and phosphoproteomic landscape of localized prostate cancer unveils distinct molecular subtypes and insights into precision therapeutics
inferred← citeshttps://doi.org/10.1080/14756366.2026.2612805openalex-snapshot
Mitogen-activated protein kinase kinase 4 (MKK4) as a promising therapeutic target in liver diseases: a review
inferred← citeshttps://doi.org/10.1136/bmjonc-2023-000192openalex-snapshot
Repurposing radiosensitising medicines for radiotherapy: an overview
inferred← citeshttps://doi.org/10.1155/2022/5041399openalex-snapshot
Targeting Tumor Microenvironment by Metal Peroxide Nanoparticles in Cancer Therapy
inferred← citeshttps://doi.org/10.1186/s12935-023-03176-2openalex-snapshot
Artificial intelligence-driven new drug discovery targeting serine/threonine kinase 33 for cancer treatment
inferred← citeshttps://doi.org/10.1186/s13040-025-00482-5openalex-snapshot
Proteome mining of Yersinia Enterocolitica for drug targets and computational inhibitor identification with ADMET, anti-inflammation potential and formulation characteristics
inferred← citeshttps://doi.org/10.13005/bbra/3455openalex-snapshot
Drug Repurposing In Oncology: Progress, Challenges, and Collaborative Pathways Toward Novel Cancer Therapies
inferred← citeshttps://doi.org/10.14202/vetworld.2023.1185-1192openalex-snapshot
Atovaquone exerts its anticancer effect by inhibiting Na+/K+-ATPase ion transport in canine cancer cells
inferred← citeshttps://doi.org/10.20944/preprints202312.1509.v1openalex-snapshot
Tailoring MAPK Pathways: New Therapeutics Avenues for Managing Alzheimer’s Diseases
inferred← citeshttps://doi.org/10.21203/rs.3.rs-3195156/v1openalex-snapshot
Unveiling the therapeutic potential of Ponatinib and Imatinib against Aurora Kinase A in gastric cancer cells
inferred← citeshttps://doi.org/10.2174/0118741045455658260423122147openalex-snapshot
ROCK2 Inhibition Underlying the Anticancer Effects of Dobutamine: A Novel Proposed Mechanism
inferred← citeshttps://doi.org/10.31219/osf.io/yqf2eopenalex-snapshot
The Significance of Text Mining in Research: A Comprehensive Review
inferred← citeshttps://doi.org/10.3390/cancers14194621openalex-snapshot
Targeting Homologous Recombination Deficiency in Ovarian Cancer with PARP Inhibitors: Synthetic Lethal Strategies That Impact Overall Survival
inferred← citeshttps://doi.org/10.3390/cancers15041044openalex-snapshot
Anti-Leukaemic Activity of Rilpivirine Is Mediated by Aurora A Kinase Inhibition
inferred← citeshttps://doi.org/10.3390/ijms23084280openalex-snapshot
Drug Repurposing in Cancer Therapy: Influence of Patient’s Genetic Background in Breast Cancer Treatment
inferred← citeshttps://doi.org/10.3390/ijms25031845openalex-snapshot
Paradigm Shift: A Comprehensive Review of Ovarian Cancer Management in an Era of Advancements
inferred← citeshttps://doi.org/10.3390/ijms27177594openalex-snapshot
A Multifunctional Chitosan-Coated Ciprofloxacin–Luteolin Lipid Nanoplatform for Photodynamic Therapy of Prostatic Cancer
inferred← citeshttps://doi.org/10.3390/ph14090853openalex-snapshot
Evaluation of Synthetic 2,4-Disubstituted-benzo[g]quinoxaline Derivatives as Potential Anticancer Agents
inferred← citeshttps://doi.org/10.3390/ph15101186openalex-snapshot
Combined In Silico and In Vitro Evidence Supporting an Aurora A Kinase Inhibitory Role of the Anti-Viral Drug Rilpivirine and an Anti-Proliferative Influence on Cancer Cells
inferred← citeshttps://doi.org/10.3892/ijmm.2024.5458openalex-snapshot
Repositioning of aripiprazole, an anti‑psychotic drug, to sensitize the chemotherapy of pancreatic cancer
inferred← citeshttps://doi.org/10.6084/m9.figshare.26652933openalex-snapshot
Additional file 1 of Artificial intelligence-driven new drug discovery targeting serine/threonine kinase 33 for cancer treatment
inferred← citeshttps://doi.org/10.6084/m9.figshare.26652936openalex-snapshot
Additional file 2 of Artificial intelligence-driven new drug discovery targeting serine/threonine kinase 33 for cancer treatment
inferred← citeshttps://doi.org/10.6084/m9.figshare.26652939openalex-snapshot
Additional file 3 of Artificial intelligence-driven new drug discovery targeting serine/threonine kinase 33 for cancer treatment
inferred← citeshttps://doi.org/10.6084/m9.figshare.26652942openalex-snapshot
Additional file 4 of Artificial intelligence-driven new drug discovery targeting serine/threonine kinase 33 for cancer treatment
inferred← citeshttps://doi.org/10.6084/m9.figshare.26652945openalex-snapshot
Additional file 5 of Artificial intelligence-driven new drug discovery targeting serine/threonine kinase 33 for cancer treatment
inferred← citeshttps://doi.org/10.64628/aa.rrjmrge7aopenalex-snapshot
We can expect more COVID drugs next year. But we’ve wasted so much time getting here
showing the first 46 of 47 · page through all 47
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.